Wu Yu-sheng, Hou Qian, Zhang Dao-jie
Hospital Affiliated to Shandong University, Jinan 250012.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Apr;26(4):308-10.
To investigate the clinical efficacy of Shexiang Injection (SI) on inflammatory reaction in patients with acute cerebral infarction (ACI).
Forty-two patients with ACI were randomly divided into two groups, 21 in each group. The control group treated with conventional therapy and the SI group treated with conventional therapy plus SI. Besides, 21 healthy people were arranged in the normal group for control. Expression of CD54 of mononuclear cell (MC-CD54) and serum level of soluble vascular cell adhesion molecule-1 (sVCAM-1) were determined and the clinical efficacy was observed dynamically before treatment and on the 7th, 14th day of the course.
Levels of MC-CD54 expression and sVCAM-1 in the ACI patients increased obviously (P < 0.01), reached the peak on the 7th day, and declined obviously on the 14th day in both groups, however, the lowering in the SI group was more significant than that in the control group (P < 0.01); and positive correlation was shown between these two indexes (P < 0.01). After treatment, score of neural defect was improved more significantly (P < 0.01), and the markedly effective and curative rate was higher in the SI group than those in the control group (P < 0.05), respectively.
SI could inhibit the subsequent inflammatory reaction, and thus improve the clinical efficacy of conventional therapy in treating patients with ACI.
探讨麝香注射液（SI）对急性脑梗死（ACI）患者炎症反应的临床疗效。
将42例ACI患者随机分为两组，每组21例。对照组采用常规治疗，SI组采用常规治疗加SI治疗。此外，安排21名健康人作为正常组进行对照。测定治疗前及病程第7天、第14天单核细胞CD54（MC-CD54）表达及血清可溶性血管细胞黏附分子-1（sVCAM-1）水平，并动态观察临床疗效。
ACI患者MC-CD54表达水平及sVCAM-1水平均明显升高（P<0.01），两组均在第7天达到峰值，第14天明显下降，但SI组下降更显著（P<0.01）；且这两个指标呈正相关（P<0.01）。治疗后，神经功能缺损评分改善更显著（P<0.01），SI组显效率和治愈率分别高于对照组（P<0.05）。
SI可抑制后续炎症反应，从而提高常规治疗对ACI患者的临床疗效。
